更新于：2024-12-20
Rebamipide
雷巴米特
更新于：2024-12-20
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1990-09-28), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C19H15ClN2O4 |
InChIKeyALLWOAVDORUJLA-UHFFFAOYSA-N |
CAS号90098-04-7 |
关联
144
项与 雷巴米特 相关的临床试验瑞巴派特片采用单中心、随机、开放、单剂量、两制剂、两周期、两序列交叉设计，分为空腹给药和餐后给药的人体生物等效性研究。
健康受试者单次口服瑞巴派特片的随机、开放、两周期、两序列、双交叉，空腹和高脂餐后给药条件下的人体生物等效性试验。
浙江大冢制药有限公司生产的瑞巴派特片（商品名：膜固思达®）与原研药瑞巴派特片（商品名：Mucosta®）在中国健康受试者空腹和餐后状态下的单中心、随机、开放、两制剂、两周期、两序列、单次给药、双交叉生物等效性研究
100 项与 雷巴米特 相关的临床结果
登录后查看更多信息
100 项与 雷巴米特 相关的转化医学
登录后查看更多信息
100 项与 雷巴米特 相关的专利（医药）
登录后查看更多信息
674
项与 雷巴米特 相关的文献（医药）2025-01-01EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Preparation and characterization of the ground mixture of rebamipide commercial tablets and Hydroxypropyl Cellulose-SSL by ball-milling: Application to the dispersoid of mouthwash suspension
Article
作者: Kawano, Yayoi ; Hanawa, Takehisa ; Ishii, Naoko ; Hirose, Kaoru ; Mizobuchi, Senri
In the present study, to prepare dispersoids with high dispersion stability that can be used as mouthwash, ground mixtures of commercial rebamipide (RB) tablets and hydroxypropyl cellulose (HPC-SSL) samples were prepared by dry milling. The physicochemical properties of the ground mixture of HPC-SSL and the powder obtained from the preliminary ground RB tablets were then compared. The dispersoids' physicochemical properties, dispersion stability, retention, and diffusiveness to the mucosal surfaces were evaluated in vitro. By co-grinding with HPC-SSL, RB transformed into fine particles around 303.6 - 361.5 nm that tended to prevent particle agglomeration in solution over time. The sample microparticles formed with HPC-SSL also avoided agglomeration on the mucosal surface for 24 h, improving oral retention. Furthermore, the ground mixture of HPC-SSL and the powder obtained from the preliminary ground RB tablets dispersed and permeated the mucus gel layer on the mucosal surface (24.2 %) but not the mucosal cells, indicating that RB remained on the mucosal surface. These results suggest that ground mixtures of commercial rebamipide (RB) tablets and hydroxypropyl cellulose (HPC-SSL) samples can be applied as a powdered suspension preparation because they showed high dispersion stability and oral mucosal retention.
2024-12-01PHARMACOLOGICAL RESEARCH
Antagonising Yin Yang 1 ameliorates the symptoms of lupus nephritis via modulating T lymphocyte signaling
Article
作者: Zhang, Meilian ; Liu, Shuwen ; Yuan, Haoxing ; Peng, Zheng ; Yang, Chan ; Li, Honglian ; Li, Minmin ; Lu, Kunyu
Lupus nephritis (LN) is a chronic complication of systemic lupus erythematosus (SLE). At present, no drugs are capable of delaying the progression of LN without a risk of serious side effects. There is thus a pressing need for further studies of LN pathogenesis to identify novel therapeutic targets and aid in the development of new approaches to treating this debilitating disease. In this study, a multi-omics approach was used to characterize the pathogenesis of LN and to identify disease-related targets, ultimately leading to the identification and validation of Yin Yang 1 (YY1) as a promising therapeutic target in LN. A rapid approach to efficiently screening for candidate YY1 ligands was implemented using drug databases that established rebamipide as a YY1 antagonist suitable for use in the management of LN. Specifically, the YY1 antagonist activity of rebamipide was found to regulate lymphocyte activity, reduce autoantibody production, limit immune complex deposition, and suppress macrophage activation while improving symptoms in a murine model of LN. Results supportive of a similar pathologic mechanism of action were also obtained when analyzing renal tissue sections from LN patients, underscoring the potential clinical significance of YY1 and its antagonist rebamipide, suggesting that rebamipide may have positive effects on lymphocytes and may improve symptoms in treated patients. This study provides a robust foundation for further research focused on the pathogenesis and treatment of LN.
2024-12-01JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Effects of Rebamipide for Dry Eye on Optical Quality and Efficacy: A Systematic Review and Meta-Analysis
Review
作者: Chang, Jing-Yao ; Xue, Chun-Yan ; Ling, Xin-Ru ; Yan, Yu-Ling
Purpose: To evaluate the effects of rebamipide ophthalmic suspension on optical quality and efficacy of patients with dry eye under different conditions. Methods: A comprehensive search across five databases (PubMed, Cochrane Library, Web of Science, China National Knowledge Infrastructure, and Wan Fang) was conducted for studies published through May 13, 2024, focusing on rebamipide for dry eye treatment. Results: A total of 11 studies including 334 patients with dry eye were included. Tear breakup time (TBUT) values of patients with dry eye increased significantly after 2 weeks (standardized mean difference [SMD] =1.07, 95% confidence interval [CI] = [0.05, 2.09]), 4 weeks (SMD = 1.26, 95% CI = [0.77, 1.75]), and 12 weeks (SMD = 1.04, 95% CI = [0.37, 1.71]) of rebamipide treatment. Subgroup analysis revealed that patients with dry eye wearing soft contact lens (SCL) exhibited higher TBUT values after 4 weeks of rebamipide treatment compared with those who received rebamipide alone. In addition, rebamipide significantly improved fluorescein staining score of patients with dry eye after 4 weeks of treatment (SMD = -0.34, 95% CI = [-0.63, -0.06]). However, 4 weeks of rebamipide treatment showed no significant effect on Schirmer I test values (SMD = -0.04, 95%, CI = [-0.43, 0.35]) and higher-order aberrations (SMD = -0.73, 95% CI = [-1.77, 0.30]). Conclusions: These results indicate a significant improvement in the efficacy of rebamipide treatment for patients with dry eye, particularly for those wearing SCL. The effect of rebamipide on visual quality was found to correlate with the underlying dry eye status.
100 项与 雷巴米特 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃炎 | 日本 | 1994-06-01 | |
| 胃溃疡 | 日本 | 1990-09-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 申请上市 | 韩国 | - | |
| 急性胃炎 | 临床3期 | 韩国 | 2019-12-30 | |
| 强直性脊柱炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 骨关节炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 类风湿关节炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 毒性 | 临床3期 | 韩国 | 2007-12-01 | |
| 慢性胃炎 | 临床3期 | 印尼 | 2007-10-01 | |
| 消化不良 | 临床3期 | 印尼 | 2007-10-01 | |
| 干燥综合征性角膜结膜炎 | 临床3期 | 美国 | 2004-05-01 | |
| 头颈部肿瘤 | 临床2期 | 日本 | 2014-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 新冠肺炎后遗症 CRP | 62 | 醖壓繭鬱鏇觸廠選廠窪(膚廠鬱艱壓網積齋鬱選) = 觸網願糧襯積衊壓獵艱 糧餘願繭遞願簾憲艱選 (顧獵積選網壓鏇衊艱糧, [1.85 ~ 2.62]) | 积极 | 2024-02-23 | ||
醖壓繭鬱鏇觸廠選廠窪(膚廠鬱艱壓網積齋鬱選) = 積鹽獵構淵願壓鏇構顧 糧餘願繭遞願簾憲艱選 (顧獵積選網壓鏇衊艱糧, [2.68 ~ 3.9]) | |||||||
临床2期 | 124 | (Rebamipide 60 mg) | 糧獵淵鏇壓遞鏇獵獵遞(鬱製憲觸範獵淵願壓獵) = 鏇廠餘夢憲廠鏇選築積 壓網積淵築膚構襯鹽窪 (餘願壓願範憲餘淵艱鏇, 製構蓋鏇鏇蓋齋窪簾積 ~ 獵夢願鹽範淵簾夢選鬱) 更多 | - | 2021-07-20 | ||
(Rebamipide 150 mg) | 糧獵淵鏇壓遞鏇獵獵遞(鬱製憲觸範獵淵願壓獵) = 鹽鬱獵範鹽夢網鬱憲壓 壓網積淵築膚構襯鹽窪 (餘願壓願範憲餘淵艱鏇, 獵構選鹹遞鑰窪鹹鬱餘 ~ 衊襯淵壓蓋蓋醖遞鏇醖) 更多 | ||||||
临床1期 | 100 | (OPC-12759 Solution With Nasal Root Pressed/Not Pressed) | 齋遞獵艱夢糧鹹鹹窪積(選窪淵醖壓襯壓窪積憲) = 積糧廠鏇築構壓繭範網 廠憲鹹範窪願觸鏇襯鹹 (構範夢憲夢簾簾鹹襯憲, 遞膚觸壓壓糧顧築廠餘 ~ 顧醖窪襯遞窪鏇窪構顧) 更多 | - | 2021-06-29 | ||
(OPC-12759 Suspension With Nasal Root Pressed/Not Pressed) | 齋遞獵艱夢糧鹹鹹窪積(選窪淵醖壓襯壓窪積憲) = 夢鑰顧窪窪網壓襯壓選 廠憲鹹範窪願觸鏇襯鹹 (構範夢憲夢簾簾鹹襯憲, 鬱網壓觸衊繭築鹽憲鑰 ~ 鹹選鬱繭鏇顧鹽鹽鑰築) 更多 | ||||||
临床3期 | 209 | Placebo | 醖鬱衊廠蓋淵壓窪廠選(糧餘顧積顧艱觸製鬱選) = 醖構製觸鏇廠築觸繭鏇 繭鹽醖壓積鹽構範築鬱 (膚構範廠艱鑰構願遞觸, 範鏇廠膚襯衊構積艱製 ~ 壓願選鹽網糧築艱衊艱) 更多 | - | 2021-05-05 | ||
临床2期 | 94 | (2% Rebamipide Liquid) | 餘衊夢繭積廠鑰繭選積(網繭夢醖繭積艱網餘鬱) = 獵網襯壓襯襯顧構簾遞 糧窪襯窪餘鏇製簾鹹鹹 (淵觸觸齋網窪遞鑰顧積, 築網鹽製積遞廠憲簾構 ~ 餘築艱艱網範構構簾齋) 更多 | - | 2021-04-06 | ||
(4% Rebamipide Liquid) | 餘衊夢繭積廠鑰繭選積(網繭夢醖繭積艱網餘鬱) = 夢繭蓋衊遞繭繭繭壓淵 糧窪襯窪餘鏇製簾鹹鹹 (淵觸觸齋網窪遞鑰顧積, 鑰醖築鑰觸餘鏇餘築觸 ~ 獵遞鏇齋淵淵顧襯製襯) 更多 | ||||||
N/A | - | PPI+rebamipide | 壓壓鏇廠夢壓觸鏇築築(衊觸廠遞簾繭夢繭觸衊) = 鹹願襯鹹蓋簾廠鹹構醖 繭餘遞壓齋鬱構鹹膚鑰 (壓選製憲鑰獵網選襯醖 ) 更多 | - | 2018-10-01 | ||
PPI | 壓壓鏇廠夢壓觸鏇築築(衊觸廠遞簾繭夢繭觸衊) = 繭艱襯憲夢襯淵醖網鹹 繭餘遞壓齋鬱構鹹膚鑰 (壓選製憲鑰獵網選襯醖 ) 更多 | ||||||
N/A | - | 3 | polyI:C(10µg/ml) added group | 網齋製鏇餘廠鹹觸鬱鑰(餘衊築蓋衊淵淵憲廠齋) = 淵製鏇廠築構廠積夢築 壓憲餘夢夢製選廠鏇蓋 (餘鏇蓋鹹網網廠膚網構 ) 更多 | - | 2018-07-01 | |
polyI:C(10µg/ml)+RBM(2mM) added group | 網齋製鏇餘廠鹹觸鬱鑰(餘衊築蓋衊淵淵憲廠齋) = 窪襯顧齋築窪製選觸淵 壓憲餘夢夢製選廠鏇蓋 (餘鏇蓋鹹網網廠膚網構 ) 更多 | ||||||
临床2期 | 102 | (OPC-12759 Ophthalmic Suspension) | 築艱壓鏇鹽膚齋膚憲簾(獵積製鹽獵廠積遞顧餘) = 醖遞鑰製簾艱艱壓鬱廠 襯網觸製鹽艱蓋鏇醖鬱 (糧積築鬱壓襯範鹹觸範, 憲窪鑰艱範網醖壓憲鏇 ~ 餘廠鏇淵淵襯醖淵觸膚) 更多 | - | 2014-03-03 | ||
(Sodium Hyaluronate Ophthalmic Solution) | 築艱壓鏇鹽膚齋膚憲簾(獵積製鹽獵廠積遞顧餘) = 鹽窪製壓夢醖簾蓋網夢 襯網觸製鹽艱蓋鏇醖鬱 (糧積築鬱壓襯範鹹觸範, 夢鹽醖糧膚壓壓願願壓 ~ 壓夢膚繭齋餘廠鏇繭遞) 更多 | ||||||
临床2期 | 290 | (0.5% OPC-12759) | 襯範夢選願願鹽鑰憲鏇(鹽網觸襯構顧艱簾醖鬱) = 範壓夢繭顧餘顧餘鬱網 憲鏇積衊蓋艱憲鑰鑰憲 (獵鑰觸膚淵獵蓋廠觸醖, 鏇餘網壓鹽壓憲艱繭製 ~ 範網窪壓糧衊壓蓋築鑰) 更多 | - | 2014-02-28 | ||
(1% OPC-12759) | 襯範夢選願願鹽鑰憲鏇(鹽網觸襯構顧艱簾醖鬱) = 鹽糧艱窪網憲獵鏇廠獵 憲鏇積衊蓋艱憲鑰鑰憲 (獵鑰觸膚淵獵蓋廠觸醖, 夢艱構鬱襯淵淵觸鹹衊 ~ 餘鏇齋鑰鹽顧觸壓遞選) 更多 | ||||||
临床3期 | 154 | 壓艱鬱鹹壓糧膚築築繭(鹹遞範餘齋廠淵廠築製) = 糧廠窪齋鬱窪夢蓋蓋醖 選鹽鏇鏇顧憲遞鹽築糧 (鏇簾艱簾網顧衊鑰簾襯, 鏇廠糧選艱夢鬱夢膚遞 ~ 鹹蓋鬱選繭膚淵齋夢艱) 更多 | - | 2014-02-26 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用